Key facts
- FlowRx’s last known valuation is $20.0M (Feb 2026).
- It has raised $8.5M; the latest was Seed Round ($8.5M) in Feb 2026.
- Notable investors include Team8.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for FlowRx
- ·The full record, as it builds
Funding rounds
No funding rounds for FlowRx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FlowRx
Developer of pharmacy workflow automation software designed for pharmacies and dispensaries. The company's platform offers a range of features, including prior authorization automation, inventory management, order entry automation, internal communication, billing and invoicing, hub-spoke workflow, and more, enabling clients to restore margins and streamline operations.
- Sector
- Information Technology
- HQ
- Needham, MA, United States
- Founded
- 2025
- Employees
- 3
- Website
- flowrx.ai/
- Ownership
- Privately Held (backing)
FlowRx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FlowRx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FlowRx in its N-PORT filings yet. We sweep new filings monthly.